RS55594B1 - Jedinjenja azetidiniloksifenilpirolidina - Google Patents

Jedinjenja azetidiniloksifenilpirolidina

Info

Publication number
RS55594B1
RS55594B1 RS20170035A RSP20170035A RS55594B1 RS 55594 B1 RS55594 B1 RS 55594B1 RS 20170035 A RS20170035 A RS 20170035A RS P20170035 A RSP20170035 A RS P20170035A RS 55594 B1 RS55594 B1 RS 55594B1
Authority
RS
Serbia
Prior art keywords
azetidinyloxyphenylpyrrolidine compounds
azetidinyloxyphenylpyrrolidine
compounds
Prior art date
Application number
RS20170035A
Other languages
English (en)
Inventor
Gary G Deng
Danwen Huang
Joshua O Odingo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS55594B1 publication Critical patent/RS55594B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
RS20170035A 2013-03-13 2014-03-07 Jedinjenja azetidiniloksifenilpirolidina RS55594B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13
PCT/US2014/021474 WO2014159012A1 (en) 2013-03-13 2014-03-07 Azetidinyloxyphenylpyrrolidine compounds
EP14712968.8A EP2970222B1 (en) 2013-03-13 2014-03-07 Azetidinyloxyphenylpyrrolidine compounds

Publications (1)

Publication Number Publication Date
RS55594B1 true RS55594B1 (sr) 2017-06-30

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170035A RS55594B1 (sr) 2013-03-13 2014-03-07 Jedinjenja azetidiniloksifenilpirolidina

Country Status (40)

Country Link
US (3) US9034864B2 (sr)
EP (2) EP2970222B1 (sr)
JP (2) JP6017708B2 (sr)
KR (2) KR101702797B1 (sr)
CN (2) CN109336865A (sr)
AP (1) AP3850A (sr)
AR (1) AR095015A1 (sr)
AU (1) AU2014241444B2 (sr)
BR (1) BR112015020222B1 (sr)
CA (1) CA2899806C (sr)
CL (1) CL2015002113A1 (sr)
CR (1) CR20150417A (sr)
CY (1) CY1120142T1 (sr)
DK (1) DK2970222T3 (sr)
DO (1) DOP2015000176A (sr)
EA (1) EA026631B1 (sr)
ES (1) ES2616470T3 (sr)
HK (1) HK1212695A1 (sr)
HR (1) HRP20170080T1 (sr)
HU (1) HUE032235T2 (sr)
IL (1) IL240904B (sr)
JO (1) JO3264B1 (sr)
LT (1) LT2970222T (sr)
MA (1) MA38410B1 (sr)
ME (1) ME02592B (sr)
MX (1) MX2015012579A (sr)
MY (1) MY180006A (sr)
NZ (1) NZ710481A (sr)
PE (1) PE20151669A1 (sr)
PH (1) PH12015502032A1 (sr)
PL (1) PL2970222T3 (sr)
PT (1) PT2970222T (sr)
RS (1) RS55594B1 (sr)
SG (2) SG10201609717YA (sr)
SI (1) SI2970222T1 (sr)
TN (1) TN2015000384A1 (sr)
TW (1) TWI617553B (sr)
UA (1) UA115583C2 (sr)
WO (1) WO2014159012A1 (sr)
ZA (1) ZA201505417B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
EP3901146A4 (en) * 2018-12-18 2022-01-19 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company PHENYLPYRROLIDINE COMPOUND AND USE THEREOF
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CN112409333A (zh) * 2019-08-23 2021-02-26 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
PL365443A1 (en) * 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
WO2007039075A2 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物

Also Published As

Publication number Publication date
MA38410A1 (fr) 2016-02-29
CN105051034B (zh) 2019-05-21
EA201591498A1 (ru) 2015-12-30
JP2016510759A (ja) 2016-04-11
PL2970222T3 (pl) 2017-06-30
BR112015020222A2 (pt) 2017-07-18
KR20150119077A (ko) 2015-10-23
UA115583C2 (uk) 2017-11-27
AP2015008699A0 (en) 2015-09-30
MY180006A (en) 2020-11-19
WO2014159012A9 (en) 2014-12-18
EP2970222B1 (en) 2016-12-21
TW201522327A (zh) 2015-06-16
NZ710481A (en) 2020-08-28
AU2014241444A1 (en) 2015-08-06
EA026631B1 (ru) 2017-04-28
EP3168216A1 (en) 2017-05-17
ZA201505417B (en) 2022-09-28
CN109336865A (zh) 2019-02-15
CL2015002113A1 (es) 2016-01-15
CA2899806C (en) 2017-07-18
CA2899806A1 (en) 2014-10-02
KR20170013411A (ko) 2017-02-06
AP3850A (en) 2016-09-30
AR095015A1 (es) 2015-09-16
US9034864B2 (en) 2015-05-19
PH12015502032A1 (en) 2016-01-18
SG11201507501YA (en) 2015-10-29
TWI617553B (zh) 2018-03-11
ES2616470T3 (es) 2017-06-13
JP6204557B2 (ja) 2017-09-27
AU2014241444B2 (en) 2016-04-07
DOP2015000176A (es) 2015-11-15
US20160122322A1 (en) 2016-05-05
KR101745304B1 (ko) 2017-06-08
HUE032235T2 (en) 2017-09-28
IL240904B (en) 2019-02-28
TN2015000384A1 (en) 2017-01-03
WO2014159012A1 (en) 2014-10-02
SG10201609717YA (en) 2017-01-27
JP2016216517A (ja) 2016-12-22
JP6017708B2 (ja) 2016-11-02
US9604967B2 (en) 2017-03-28
CR20150417A (es) 2015-09-16
IL240904A0 (en) 2015-10-29
SI2970222T1 (sl) 2017-02-28
LT2970222T (lt) 2017-03-27
ME02592B (me) 2017-06-20
CN105051034A (zh) 2015-11-11
US9266859B2 (en) 2016-02-23
US20140275002A1 (en) 2014-09-18
HRP20170080T1 (hr) 2017-03-10
HK1212695A1 (zh) 2016-06-17
PE20151669A1 (es) 2015-11-12
MA38410B1 (fr) 2016-09-30
DK2970222T3 (en) 2017-02-27
EP2970222A1 (en) 2016-01-20
US20150133423A1 (en) 2015-05-14
KR101702797B1 (ko) 2017-02-06
MX2015012579A (es) 2016-01-20
PT2970222T (pt) 2017-02-08
JO3264B1 (ar) 2018-09-16
BR112015020222B1 (pt) 2020-07-14
BR112015020222A8 (pt) 2018-01-23
CY1120142T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
HRP20171851T1 (hr) Spojevi tetrahidropirolotiazina
HK1222658A1 (zh) 氰基三唑化合物
GB201309085D0 (en) Compounds
GB201310542D0 (en) Compounds
GB201311951D0 (en) Compounds
GB201309508D0 (en) Compounds
HK1212695A1 (zh) 氮雜環丁烷氧基苯基吡咯烷化合物
GB201320636D0 (en) Compounds
GB201319363D0 (en) Compounds
GB201317619D0 (en) Compounds
GB201312901D0 (en) Compounds
GB201311953D0 (en) Compounds
GB201318461D0 (en) Compounds
GB201316014D0 (en) Compounds
GB201310460D0 (en) Compounds
GB201306794D0 (en) Compounds
GB201322855D0 (en) Compounds
GB201322028D0 (en) Compounds
GB201321553D0 (en) Compounds
GB201321554D0 (en) Compounds
GB201321283D0 (en) Compounds
GB201318323D0 (en) Compounds
GB201318143D0 (en) Compounds
GB201317118D0 (en) Compounds
GB201316717D0 (en) Compounds